Francois-Xavier Mahon
Prof Francois-Xavier Mahon is an expert in Hematology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Francois-Xavier Mahon in the top 1% of experts worldwide for Leukemia. Francois-Xavier Mahon has authored 483 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 2 of them ongoing. SLR score: 1,877 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1992 - 2026
Number : 483
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi-LMC study. PMID 42549430 — cells, leukemia, leukemia, myeloid, therapeutics, clone cells, leukemia, myelogenous, chronic, bcr-abl positive, mutation | Hemasphere | 2026 | 0 |
| Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results. PMID 42463944 — safety, incidence, leukemia, leukemia, myeloid, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive | Leukemia | 2026 | 0 |
| Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia. PMID 42454992 — cells, transcriptome, leukemia, machine learning, leukemia, myeloid, therapeutics, learning, leukemia, myelogenous, chronic, bcr-abl positive | J Clin Oncol Top journal | 2026 | 1 |
| Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. PMID 42315627 — cells, genes, communication, adaptive immunity, leukemia, biomarkers, leukemia, myeloid, immunity, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive | Leukemia | 2026 | 3 |
| Chronic Myeloid Leukemia in Low- and Middle-Income Countries. PMID 42235030 — income, leukemia, leukemia, myeloid, leukemia, myelogenous, chronic, bcr-abl positive | N Engl J Med Top journal | 2026 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia 2022-502514-86-00 — thrombocythemia, essential, safety, thrombocytosis, primary myelofibrosis | Phase 1 | Recruiting | 2024 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph CML CP NCT04971226 — mesylates, dasatinib, multiple chronic conditions, leukemia, tablets, capsules, leukemia, myeloid, therapeutics, imatinib mesylate, chromosomes, leukemia, myelogenous, chronic, bcr-abl positive, philadelphia chromosome | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map